Artera
Artera develops FDA-cleared multimodal AI cancer diagnostic tests that combine digital pathology images with clinical data to predict treatment benefit and prognosis, serving urologists, oncologists, and pathology labs across all 50 US states and international markets.
- Company typePrivate
- Founded2021
- HeadquartersLos Altos, United States
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What Artera does
Artera is a precision medicine company that develops multimodal artificial intelligence (MMAI) tests for personalized cancer treatment decision support. Its core technology combines deep-learning analysis of digitized H&E histopathology images with structured clinical variables to generate predictive and prognostic risk scores — for example, predicting which localized prostate cancer patients will benefit from hormone therapy alongside radiation, or estimating 5- and 10-year distant metastasis risk in early-stage breast cancer patients. The portfolio spans four FDA-cleared/authorized products — ArteraAI Prostate Test (Biopsy), ArteraAI Prostate Test (Post-RP), ArteraAI Prostate Test (mHSPC), and ArteraAI Breast Cancer Test — plus an ArteraAI Bladder Test in development via a Photocure partnership. All products are delivered as laboratory-developed tests from a single CLIA-certified, CAP-accredited laboratory in Jacksonville, Florida, with reimbursement from Medicare Part B and commercial payers including multiple BCBS plans and Centene.
Artera generates revenue on a per-test basis through insurance reimbursement and operates a financial assistance program tiered by household income for uninsured and commercially insured patients. Go-to-market combines direct enterprise field sales to urology practices, oncology centers, and pathology labs across all 50 US states with channel partnerships — most notably a Tempus integration that embeds ArteraAI Prostate into Tempus' solid tumor genomic profiling orders — plus international distribution in the UK, EU, Australia, Israel, and Puerto Rico. Adoption is supported by presence at major oncology and urology conferences (ASCO, ASTRO, AUA, SUO), peer-reviewed clinical publications, and an NCCN Clinical Practice Guidelines recommendation — the first and only AI test to achieve this status for prostate cancer. The company is venture-backed (~$135M raised to date from Coatue, Johnson & Johnson Innovation, Breyer Capital, and others), holds SOC 2 Type II and HIPAA compliance, and operates from its Los Altos, California headquarters.
Artera firmographics
Firmographics- Name
- Artera
- Legal name
- Artera
- Website
- https://artera.ai
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Artera develops FDA-cleared multimodal AI cancer diagnostic tests that combine digital pathology images with clinical data to predict treatment benefit and prognosis, serving urologists, oncologists, and pathology labs across all 50 US states and international markets.
- Ownership category
- akta.pro rank
Artera industry classification
Industry- Product category
- AI-Powered Cancer Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
- akta.pro secondary industry
- Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN)
Keywords
Where Artera is headquartered
LocationHeadquarters
- HQ city
- Los Altos
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Artera business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Laboratory Diagnostic Testing Services: CLIA-certified laboratory developed test (LDT) service performing AI-powered cancer tests. Revenue generated through Medicare Part B reimbursement (zero out-of-pocket for covered patients) and commercial insurance claims submission.
- Laboratory Testing Reimbursement: Revenue from insurance reimbursements including Medicare Part B established payment rate and commercial payer contracts with major insurers including multiple BCBS plans, Centene, and other health plans.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Outcome Based/ Performance | Per test | Medicare Part B Coverage |
| Outcome Based/ Performance | Per test | Commercial Insurance Coverage |
| Hybrid | Per test | Financial Assistance Program |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels4 records
Artera product offering
Product offeringCore offering
Artera develops and delivers AI-powered predictive and prognostic cancer diagnostic tests under the ArteraAI brand. Using its Multimodal Artificial Intelligence (MMAI) platform, the company analyzes digitized H&E histopathology images combined with patient clinical data to generate personalized risk scores for prostate and breast cancer patients. Tests are offered as CLIA-certified laboratory developed tests through a single Jacksonville, FL laboratory, with FDA De Novo authorization for prostate cancer and FDA clearance for breast cancer. The company sells directly to urologists, oncologists, radiation oncologists, academic medical centers, and pathology labs across all 50 US states and internationally.
Product overview
Artera is a precision medicine company offering a unified platform of AI-powered cancer diagnostic tests under the ArteraAI brand. The portfolio includes four FDA-cleared/authorized products: ArteraAI Prostate Test (Biopsy) for localized prostate cancer, ArteraAI Prostate Test (Post-RP) for post-prostatectomy recurrence, ArteraAI Prostate Test (mHSPC) for metastatic hormone-sensitive prostate cancer, and ArteraAI Breast Cancer Test for early-stage breast cancer. All products leverage the MMAI (Multimodal Artificial Intelligence) platform that combines digital histopathology images with clinical data. The tests are laboratory-developed tests (LDT) services performed at Artera's CLIA-certified laboratory in Jacksonville, FL, and are also available through partnerships with Tempus and Acupath Laboratories.
Differentiator
Problem solved
Functional benefit
Brands
- ArteraAI Prostate Test: AI-powered digital pathology test for prostate cancer prognosis and treatment decision support
- ArteraAI Breast
- ArteraAI Bladder Test
- ArteraAI
Products and services
- ArteraAI Prostate Test (Biopsy) Multimodal AI test that analyzes digitized biopsy images and clinical data to predict therapeutic benefit, inform active surveillance decisions, and prognosticate long-term outcomes for patients with localized prostate cancer. First AI test recommended in NCCN Guidelines for Prostate Cancer.
- ArteraAI Prostate Test (Post-RP) AI-powered test for patients with recurrent prostate cancer after radical prostatectomy that provides estimates of long-term outcomes and predicts benefit from adding hormone therapy to salvage radiation therapy.
- ArteraAI Prostate Test (mHSPC) First AI-powered test providing individualized 5-year prostate cancer-specific mortality risk estimates for patients with metastatic hormone-sensitive prostate cancer, to guide treatment intensity and duration decisions between doublet and triplet therapy.
- ArteraAI Breast Cancer Test FDA-cleared digital pathology-based risk stratification tool for early-stage hormone receptor-positive, HER2-negative invasive breast cancer that generates 5- and 10-year distant metastasis risk estimates and predicts chemotherapy benefit for node-negative patients 50 years or older.
- ArteraAI Bladder Test AI-powered digital pathology test for bladder cancer diagnostics using multimodal AI histopathology biomarkers, being developed in partnership with Photocure for non-muscle invasive bladder cancer patients.
Quantifiable outcome
- Results within 1-2 days vs traditional 6-week genomic test timeline
- +4 more outcomes
Companies that use Artera
Customer profileNamed customers6 records
Segments5 records
Ideal customer profiles4 records
Artera technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability6 records
Feature5 records
Artera partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Photocure ASAcoreJoint research initiative combining Photocure's blue light cystoscopy (BLC) registry data with Artera's AI-powered ArteraAI Bladder Test for bladder cancer diagnostics. Collaboration aims to validate and develop multimodal AI histopathology biomarkers for non-muscle invasive bladder cancer patients. Partnership provides Artera access to high-quality data from Photocure's U.S. BLC registry.
- NHS Hospitals (Vanguard Path Study)core£1.9 million Vanguard Path study funded by Prostate Cancer UK and led by University of Oxford testing ArteraAI Prostate Biopsy Assay in NHS hospitals. Three-year study involving biopsies from over 4,000 men. Initial sites: North Bristol NHS Trust, Oxford University Hospitals NHS Foundation Trust, and NHS Greater Glasgow and Clyde.
- TempuscoreCommercial collaboration enabling Tempus to offer ArteraAI Prostate Test through its genomic profiling platform. Physicians using Tempus xT CDx, xT, or xR comprehensive genomic profiling can add ArteraAI Prostate Test to orders. First externally developed digital pathology algorithm in Tempus ecosystem. Test fully integrated into Tempus solid tumor portfolio.
- Federally Qualified Health Centers (FQHCs)minorPartnership with 12+ FQHC organizations expanding support for underserved communities. Focus on increasing access to AI-powered cancer diagnostics for safety-net populations.
- Amazon Web Services (AWS)coreCloud infrastructure provider enabling Artera to develop and scale its FDA-authorized ArteraAI Prostate platform. AWS infrastructure supports global compliance and operational efficiency for the AI-powered diagnostics platform.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
Artera competitors and assessment
Company assessmentDirect peers
- Tempus AI: AI-driven precision medicine company offering genomic profiling (xT, xR) and increasingly digital pathology algorithms. Direct distribution partner to Artera and overlapping customer base in oncology; competes in AI-enabled cancer diagnostics.
- Veracyte (Decipher Biosciences): Genomic diagnostics company with the Decipher Prostate and Decipher Bladder tests, directly competing with ArteraAI in prostate and urologic cancer risk stratification for treatment decisions.
- Exact Sciences (Oncotype DX): Major cancer diagnostics player with Oncotype DX genomic tests for breast and prostate cancer, directly competing for oncologist adoption and reimbursement in the same indication space as ArteraAI.
- Myriad Genetics (Prolaris): Provides Prolaris, an established gene-expression test for prostate cancer prognosis, directly competing with ArteraAI Prostate in localized prostate cancer risk stratification.
- Guardant Health: Liquid biopsy and oncology testing company; competes in advanced prostate cancer (e.g., Guardant360) and is expanding into minimal residual disease and early detection, overlapping with Artera's oncology customer base.
- Caris Life Sciences: Molecular profiling and AI-driven oncology company offering MI Profile and Caris Assure, competing in AI-enabled precision oncology and cancer risk stratification across tumor types.
- Natera: Cell-free DNA and oncology testing company (Signatera MRD test) competing in precision oncology workflows and increasingly in early cancer detection, sharing the oncology clinician customer base.
Broad incumbents
- Foundation Medicine (Roche): Broadest U.S. provider of comprehensive genomic profiling for solid tumors under Roche; competing in oncology decision support with a much larger portfolio and integrated pharma services.
Emerging players
- Paige.AI: AI digital pathology company with FDA-authorized prostate cancer detection algorithm; closest pure-play competitor in AI-on-H&E diagnostics, sharing urology and pathology end users with Artera.
- PathAI: AI pathology platform company partnering with biopharma and diagnostics; adjacent competitor in AI-powered histopathology and a potential partner in digital pathology infrastructure.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Artera social profiles
Digital presenceArtera compliance and trust
Trust signalCompliance3 records
Artera financial estimates
Financial estimateRevenue estimate
Valuation estimate
Artera leadership team
Management profileNumber of profiles
Profiles18 records
Artera subsidiaries and ownership
Company hierarchySubsidiaries1 record
Artera funding detail
Funding detailFunding overview
Funding rounds2 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Artera M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Artera
What does Artera do?
Artera develops and delivers AI-powered predictive and prognostic cancer diagnostic tests under the ArteraAI brand. Using its Multimodal Artificial Intelligence (MMAI) platform, the company analyzes digitized H&E histopathology images combined with patient clinical data to generate personalized risk scores for prostate and breast cancer patients. Tests are offered as CLIA-certified laboratory developed tests through a single Jacksonville, FL laboratory, with FDA De Novo authorization for prostate cancer and FDA clearance for breast cancer. The company sells directly to urologists, oncologists, radiation oncologists, academic medical centers, and pathology labs across all 50 US states and internationally.
Is Artera a public or private company?
Artera is a private company. It is classified as venture growth investor backed and is currently operating.
When was Artera founded?
Artera was founded in 2021. It employs 101 to 250 people.
Where is Artera based?
Artera is headquartered in Los Altos, United States, in the North America region.
How does Artera make money?
Two revenue lines are on record. Laboratory Diagnostic Testing Services are the primary driver. The others are laboratory Testing Reimbursement.
Who are Artera's main competitors?
Direct peers on record are Tempus AI, Veracyte (Decipher Biosciences), Exact Sciences (Oncotype DX), Myriad Genetics (Prolaris), Guardant Health, Caris Life Sciences and Natera. Foundation Medicine (Roche) is listed as a broad incumbent. Emerging players are Paige.AI and PathAI.
Does Artera have an API?
No public API is recorded for Artera.
What industry is Artera in?
Artera's product category is AI-Powered Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays. Its NAICS code is 621511 and its SIC code is 8071.